Results 51 to 60 of about 12,009,787 (277)

A Multi-Level Analysis of World Scientific Output in Pharmacology [PDF]

open access: yes, 2012
The purpose of this chapter is to analyse international research in “pharmacology, toxicology and pharmaceutics” (hereafter pharmacology) on the basis of the scientific papers listed in the Scopus multidisciplinary database.
Ovalle-Perandones, María-Antonia   +2 more
core   +2 more sources

Modeling and Simulation of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended‐Release and Immediate‐Release Formulations in Healthy Adults Using the Quantitative Systems Toxicology Software Platform DILIsym

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Acetaminophen (APAP) has been formulated as immediate‐, modified‐, and extended‐release tablets (APAP‐IR, ‐MR, and ‐ER, respectively). However, there was concern that APAP‐MR previously available in Europe could form a bezoar after a large overdose ...
James J. Beaudoin   +9 more
doaj   +1 more source

Quantitative Systems Pharmacology: A Case for Disease Models

open access: yesClinical Pharmacology & Therapeutics, 2016
Quantitative systems pharmacology (QSP) has emerged as an innovative approach in model‐informed drug discovery and development, supporting program decisions from exploratory research through late‐stage clinical trials. In this commentary, we discuss the unique value of disease‐scale “platform” QSP models that are amenable to reuse and repurposing to ...
Musante, CJ   +5 more
openaire   +2 more sources

Degradation mechanism of the von Willebrand factor A2 domain by nattokinase

open access: yesFEBS Letters, EarlyView.
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto   +3 more
wiley   +1 more source

Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus : A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms

open access: yes, 2014
Recent clinical studies suggest sustained treatment effects of interleukin-1β (IL-1β)-blocking therapies in type 2 diabetes mellitus. The underlying mechanisms of these effects, however, remain underexplored.
Penney, Mark   +11 more
core   +1 more source

In vitro to clinical translation of combinatorial effects of doxorubicin and dexrazoxane in breast cancer: a mechanism-based pharmacokinetic/pharmacodynamic modeling approach

open access: yesFrontiers in Pharmacology, 2023
Dexrazoxane (DEX) is the only drug clinically approved to treat Doxorubicin-induced cardiotoxicity (DIC), however its impact on the anticancer efficacy of DOX is not extensively studied.
Hardik Mody   +4 more
doaj   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

open access: yesFEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg   +14 more
wiley   +1 more source

Translational Systems Pharmacology Studies in Pregnant Women

open access: yes, 2017
Pregnancy involves rapid physiological adaptation and complex interplay between mother and fetus. New analytic technologies provide large amounts of genomic, proteomic, and metabolomics data.
Haas, David M.   +5 more
core   +1 more source

An Integrative Mechanistic Model of Type 1 IFN‐Mediated Inflammation in Systemic Lupus Erythematosus

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Type I interferon (IFN1) pathway–targeting therapies represent a highly promising class of remedies for the treatment of systemic lupus erythematosus. However, the overall clinical benefit of these compounds is afflicted by marked variability.
Alina Volkova   +7 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy